Literature DB >> 26548494

The behavioral profile of spice and synthetic cannabinoids in humans.

Helge H Müller1, Johannes Kornhuber2, Wolfgang Sperling2.   

Abstract

The use of synthetic cannabinoids (spice) is increasing. The number of descriptions of (new) clinical side effects is also increasing. We screened relevant publications for articles about spice with a focus on the clinical manifestations of the use of this drug. Spice creates diffuse psychiatric and somatic effects that are only partially similar to those of natural cannabinoids. Most of the observed effects are related to sympathomimetic-cardiac effects and neuropsychiatric manifestations. Clinical treatment is primarily based on intensive apparative and laboratory monitoring and supportive therapy. Because the exact active ingredients of spice are often difficult to determine with standard specific toxicology testing, the assessment and analysis of consumed substances by specialized laboratories is recommended.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Neuropsychiatric side-effects; Somatic effects; Spice; Synthetic cannabinoids; Treatment

Mesh:

Substances:

Year:  2015        PMID: 26548494     DOI: 10.1016/j.brainresbull.2015.10.013

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  9 in total

1.  Ischaemic cardiomyopathy and embolic stroke in a young adult with suspected synthetic cannabinoid use.

Authors:  Sumera Khan; Ahmad Hanif; Michael F Wilson
Journal:  BMJ Case Rep       Date:  2018-06-07

2.  Chronic Use of Synthetic Cannabinoids Is Associated With Impairment in Working Memory and Mental Flexibility.

Authors:  Koby Cohen; Yaniv Mama; Paola Rosca; Albert Pinhasov; Aviv Weinstein
Journal:  Front Psychiatry       Date:  2020-06-30       Impact factor: 4.157

3.  Acute Rhabdomyolysis Following Synthetic Cannabinoid Ingestion.

Authors:  Demilade A Adedinsewo; Oluwaseun Odewole; Taylor Todd
Journal:  N Am J Med Sci       Date:  2016-06

4.  Psychostimulant Effect of the Synthetic Cannabinoid JWH-018 and AKB48: Behavioral, Neurochemical, and Dopamine Transporter Scan Imaging Studies in Mice.

Authors:  Andrea Ossato; Licia Uccelli; Sabrine Bilel; Isabella Canazza; Giovanni Di Domenico; Micol Pasquali; Gaia Pupillo; Maria Antonietta De Luca; Alessandra Boschi; Fabrizio Vincenzi; Claudia Rimondo; Sarah Beggiato; Luca Ferraro; Katia Varani; Pier Andrea Borea; Giovanni Serpelloni; Fabio De-Giorgio; Matteo Marti
Journal:  Front Psychiatry       Date:  2017-08-04       Impact factor: 4.157

Review 5.  Cannabis, cannabinoids, and health.

Authors:  Genevieve Lafaye; Laurent Karila; Lisa Blecha; Amine Benyamina
Journal:  Dialogues Clin Neurosci       Date:  2017-09       Impact factor: 5.986

6.  Assessing the experience of using synthetic cannabinoids by means of interpretative phenomenological analysis.

Authors:  Szilvia Kassai; Judit Nóra Pintér; József Rácz; Brigitta Böröndi; Tamás Tóth-Karikó; Kitti Kerekes; V Anna Gyarmathy
Journal:  Harm Reduct J       Date:  2017-02-10

7.  Broad and Region-Specific Impacts of the Synthetic Cannabinoid CP 55,940 in Adolescent and Adult Female Mouse Brains.

Authors:  Emma Leishman; Michelle N Murphy; Michelle I Murphy; Ken Mackie; Heather B Bradshaw
Journal:  Front Mol Neurosci       Date:  2018-11-27       Impact factor: 5.639

Review 8.  Overview of Synthetic Cannabinoids ADB-FUBINACA and AMB-FUBINACA: Clinical, Analytical, and Forensic Implications.

Authors:  Carolina Lobato-Freitas; Andreia Machado Brito-da-Costa; Ricardo Jorge Dinis-Oliveira; Helena Carmo; Félix Carvalho; João Pedro Silva; Diana Dias-da-Silva
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-25

9.  Nausea-Induced Conditioned Gaping Reactions in Rats Produced by High-Dose Synthetic Cannabinoid, JWH-018.

Authors:  Marieka V DeVuono; Kelly M Hrelja; Gavin N Petrie; Cheryl L Limebeer; Erin M Rock; Matthew N Hill; Linda A Parker
Journal:  Cannabis Cannabinoid Res       Date:  2020-12-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.